RAD9A antibody
Principal name
RAD9A antibody
Alternative names for RAD9A antibody
RAD-9A, Cell cycle checkpoint control protein RAD9A, EC=3.1.11.2, DNA repair exonuclease rad9 homolog A
Ncbi ID
Available reactivities
Available hosts
Available applications
Immunocytochemistry/Immunofluorescence (ICC/IF), Western blot / Immunoblot (WB), Enzyme Immunoassay (E), Frozen Sections (C), Immunoprecipitation (IP), Paraffin Sections (P), Flow Cytometry (F)
Background of RAD9A antibody
Cells respond to DNA damage by activating a network of signaling pathways that control cell cycle progression and DNA repair. Cell cycle checkpoints are mechanisms that transiently delay cell cycle progression when DNA is damaged or DNA replication is incomplete. In the fission yeast Schizosaccharomyces pombe, a group of six such checkpoint control genes have been identified and include rad1+, rad3+, rad9+, rad17+, rad26+ and hus1+. Mutations in any one of these genes render cells sensitive to gamma-rays, UV light or the DNA synthesis inhibitor hydroxyurea (HU) and eliminate the ability of cells to delay entry into mitosis after treatment with these agents. All of these genes apparently link abnormal DNA structures to cell cycle control. As for cell cycle-related genes in general, these checkpoint control genes are highly conserved throughout evolution. Human and mouse versions of several of the S.pombe genes have been isolated, providing strong evidence that checkpoint control mechanisms are also highly conserved. In mammals, these genes are thought to maintain genomic stability, especially in the presence of DNA damage. Therefore, when these genes are altered, genomic instability may occur and lead to cancer. The biochemical activities of most of the checkpoint control gene products are not well established, although progress has been made towards learning more about their function. For example, examination of the structure of the protein encoded by human or S.pombe rad9 reveals a BH3-like domain in the N-terminal region that can bind the anti-apoptotic proteins Bcl-2 and Bcl-XL. Furthermore, overexpression of the gene from either organism in human cells can cause apoptosis in a BH3 domain-dependent manner. Both S.pombe and human versions of the protein can bind two other checkpoint control proteins, Hus1p (HUS1p) and Rad1p (RAD1p). Human RAD9 protein binds HUS1 and RAD1 proteins at its C-terminal region, suggesting that RAD9 has at least two functional domains, one involved in apoptosis and the other in cell cycle checkpoint control. Rad9 conveys the checkpoint signal by activating Rad53p and Chk1p; is hyperphosphorylated by Mec1p and Tel1p; and is a potential Cdc28p substrate.
General readings
This product has been used in:Komatsu K et al. PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition. Oncogene 19:5291-7 (2000). PubMed PMID: 11077446
General / background references:Brondello JM et al. Basis for the checkpoint signal specificity that regulates Chk1 and Cds1 protein kinases. Mol Cell Biol 19:4262-9 (1999). PubMed PMID: 10330167
Russell P Checkpoints on the road to mitosis. Trends Biochem Sci 23:399-402 (1998). PubMed PMID: 9810229
Lieberman HB et al. A human homolog of the Schizosaccharomyces pombe rad9+ checkpoint control gene. Proc Natl Acad Sci U S A 93:13890-5 (1996). PubMed PMID: 8943031
Western Blot: Rad9 Antibody [NB100-193] - Western blot analysis of Rad9 on HeLa whole cell extracts using NB100-193.
Western Blot: Rad9 Antibody [NB100-193] - Western blot analysis of Rad9 in U20S cell lysates using NB100-193.
Figure 1. Immunoblotting. Affinity purified phosphospecific antibody to yeast Rad9 at pS1260 was used at a 1:200 dilution incubated overnight at 4°C to detect Rad9 by Western blot. Lanes were loaded with 50 ng each of recombinant GST fusion protein containing S. cerevisiae Rad9 (aa 991-1309 ~60 kDa) on a 4-20% Criterion gel for SDS-PAGE as follows: Lane 1-non-phosphorylated wild type yeast Rad9, Lane 2-in vitro phosphorylated wild type yeast Rad9, Lane 3-non-phosphorylated S1129A/S1260A double mutant Rad9, Lane 4 - in vitro phosphorylated S1129A/S1260A double mutant. Phosphorylation of Rad9 was by treatment with ATP and Rad53 kinase. Rad53 kinase autophosphorylates and appears cross reactive as it is detected on the blot as 90 and 110 kDa bands (asterisk). Detection occurred using a 1:5,000 dilution of IRDye TM800 conjugated Donkey anti-Rabbit IgG for 1h at room temperature. LICOR's Odyssey® Infrared Imaging System was used to scan and process the image. Other detection systems will yield similar results
Figure 2. Summary Table. Checkpoints are mechanisms that impose delays in the cell cycle in response to DNA damage or defects in DNA replication, to ensure that mitotic transmission is error-free. Failure to delay the cell cycle in the presence of damage converts an easily reparable DNA lesion into one far more deleterious, provoking genomic instability or cell death. This figure shows a summary of our current knowledge about the DNA damage checkpoints in yeast. Genetic analysis of the pathway has allowed classification of its components into 'Sensors', which detect different sorts of damage, 'Signal transducers' which are signal-integrating kinases, and 'Targets' which carry out the essential functions of suppressing progress through the cell cycle (i.e. inducing repair genes and preventing late origin firing or sister chromatid segregation. Contributed by C. Frei and K. Shimada, laboratory of S. Gasser, U. Geneva.
Figure 1. Summary Table.Checkpoints are mechanisms thatimpose delays in the cell cycle inresponse to DNA damage or defectsin DNA replication, to ensure thatmitotic transmission is error-free.Failure to delay the cell cycle in thepresence of damage converts aneasily reparable DNA lesion into onefar more deleterious, provokinggenomic instability or cell death. Thisfigure shows a summary of our currentknowledge about the DNA damagecheckpoints in yeast. Genetic analysisof the pathway has allowedclassification of its components into'Sensors', which detect different sortsof damage, 'Signal transducers' whichare signal-integrating kinases, and'Targets' which carry out the essentialfunctions of suppressing progressthrough the cell cycle (i.e. inducingrepair genes and preventing late originfiring or sister chromatid segregation.Contributed by C. Frei and K.Shimada, laboratory of S. Gasser, U.Geneva.
Figure 1. Immunoblotting. Affinity purified antibody to yeast Rad9 (pan reactive) was used at a 1:200 dilution incubated 8 h at room temperature to detect Rad9 by Western blot. Lanes were loaded with 50 ng each of recombinant GST fusion protein containing S. cerevisiae Rad9 (aa 991-1309 ~60 kDa) on a 4-20% Criterion gel for SDS-PAGE as follows: Lane 1-non-phosphorylated wild type yeast Rad9, Lane 2-in vitro phosphorylated wild type yeast Rad9, Lane 3-non-phosphorylated S1129A/S1260A double mutant Rad9, Lane 4-in vitro phosphorylated S1129A/S1260A double mutant. Phosphorylation of Rad9 was by treatment with ATP and Rad53 kinase. Detection occurred using a 1:5,000 dilution of IRDye TM800 conjugated Donkey anti-Rabbit IgG for 1h at room temperature. LICOR's Odyssey® Infrared Imaging System was used to scan and process the image. Other detection systems will yield similar results.
Figure 2. Summary Table. Checkpoints are mechanisms that impose delays in the cell cycle in response to DNA damage or defects in DNA replication, to ensure that mitotic transmission is error-free. Failure to delay the cell cycle in the presence of damage converts an easily reparable DNA lesion into one far more deleterious, provoking genomic instability or cell death. This figure shows a summary of our current knowledge about the DNA damage checkpoints in yeast. Genetic analysis of the pathway has allowed classification of its components into 'Sensors', which detect different sorts of damage, 'Signal transducers' which are signal-integrating kinases, and 'Targets' which carry out the essential functions of suppressing progress through the cell cycle (i.e. inducing repair genes and preventing late origin firing or sister chromatid segregation. Contributed by C. Frei and K. Shimada, laboratory of S. Gasser, U. Geneva.
Western Blot: RAD9A Antibody [NB100-57077] - NB100-57077 (0.3ug/ml) staining of A431cell lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Western blot analysis of RAD9 recombinant protein using RAD9 antibody at 2 ug/ml. Human tissue TMA was used for this test.
Formalin-fixed, paraffin-embedded human prostate adenocarcinoma stained with RAD9 antibody at 5 ug/ml.
Western Blot: Rad9 Antibody [GTX30297] - Analysis of Rad9 on HeLa whole cell extracts using GTX30297
Western Blot: RAD9 Antibody (93A535) [NB120-13600] - Western blot analysis of Rad9 using NB120-13600 at 2 ug/ml against recombinant Rad9.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with RAD9A (phospho S272) polyclonal antibody ( Cat # PAB0581 ) which was peroxidase-conjugated to the secondary antibody followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. HC = hepatocarcinoma.
The RAD9A (phospho S272) polyclonal antibody ( Cat # PAB0581 ) is used in Western blot to detect Phospho-RAD9A-S272 in HL-60 ( left ), Hela ( middle ), and Y-79 ( right ) cell lysates.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with RAD9A (phospho S277) polyclonal antibody ( Cat # PAB0582 ) which was peroxidase-conjugated to the secondary antibody followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. HC = hepatocarcinoma.
The RAD9A (phospho S277) polyclonal antibody ( Cat # PAB0582 ) is used in Western blot to detect Phospho-RAD9A-S277 in Y-79 cell lysate
Formalin-fixed and paraffin-embedded human cancer tissue reacted with RAD9A (phospho S328) polyclonal antibody ( Cat # PAB0583 ) which was peroxidase-conjugated to the secondary antibody followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma.
The RAD9A (phospho S328) polyclonal antibody ( Cat # PAB0583 ) is used in Western blot to detect Phospho-RAD9A-S328 in HL-60 ( left ) and Y-79 ( right ) cell lysates
RAD9A (phospho S328) polyclonal antibody ( Cat # PAB0583 ). Western blot analysis of RAD9A expression in human liver.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with RAD9A (phospho S387) polyclonal antibody ( Cat # PAB0588 ) which was peroxidase-conjugated to the secondary antibody followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma.
The RAD9A (phospho S387) polyclonal antibody ( Cat # PAB0588 ) is used in Western blot to detect Phospho-RAD9A-S387 in Y-79 ( left ) and Hela ( right ) cell lysate.
The RAD9A (phospho Y28) polyclonal antibody ( Cat # PAB0589 ) is used in Western blot to detect Phospho-RAD9A-Y28 in HL-60 cell lysate
Western blot analysis of RAD9A polyclonal antibody ( Cat # PAB4457 ) in HeLa cell line lysates ( 35 µg/lane ) . Rad9 ( arrow ) was detected using the purified RAD9A polyclonal antibody ( Cat # PAB4457 ) ( 1 : 60 dilution ) .
RAD9A polyclonal antibody ( Cat # PAB7169 ) ( 0.3 µg/ml ) staining of A-431 cell lysate ( 35 µg protein in RIPA buffer ) . Primary incubation was 1 hour. Detected by chemiluminescence.
Western blot analysis of RAD9A. Using RAD9A monoclonal antibody, clone 93A535 ( Cat # MAB0063 ) at 2 µg/ml against recombinant RAD9.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
LEFT: Western blot analysis of anti-Rad9 BH3 domain Pab (Cat. #AP11314PU-N) in HL-60 cell lysate. Rad9 BH3 domain (arrow) was detected using purified Pab. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence. RIGHT: Western blot analysis of Rad9(arrow) using rabbit polyclonal Rad9 BH3 domain Pab (Cat. #AP11314PU-N). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the Rad9 gene (Lane 2) (Origene Technologies).
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
The anti-Phospho-Rad9 pSer272 Pab (Cat.#AP12684PU-N) is used in Western blot to detect Phospho-Rad9-S272 in HL60 (left), Hela(middle), and Y79(right)tissue lysates.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
The anti-Phospho-Rad9 pSer277 Pab (Cat.#AP12685PU-N) is used in Western blot to detect Phospho-Rad9 pSer277 in Y79 tissue lysate
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
(LEFT) The anti-Phospho-Rad9-Ser328 Pab (Cat. #AP12686PU-N) is used in Western blot to detect Phospho-Rad9-S328 in HL60 (left) and Y79 (right) tissue lysates. (RIGHT) Dot blot analysis of anti-Phospho-Rad9-Ser328 Antibody (Cat.#AP12686PU-N) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
The anti-Phospho-Rad9 pSer387 Pab (Cat.#AP12691PU-N) is used in Western blot to detect Phospho-Rad9-S387 in Y79 (left) and Hela (right) tissue lysate
The anti-Phospho-Rad9 pTyr28 Pab (Cat.#AP12692PU-N) is used in Western blot to detect Phospho-Rad9 pTyr28 in HL30 tissue lysate
Western blot analysis of anti-Rad9 Antibody (Center) in Hela cell line lysates (35ug/lane). Rad9 (arrow) was detected using the purified Pab (1:60 dilution).
AP16660PU-N RAD9A antibody staining of A431cell lysate at 0.3 µg/ml (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
Western blot analysis of RAD9A in U-2 OS cell lysate with RAD9A polyclonal antibody ( Cat# PAB12050 ).
Western Blot: Rad9 Lysate [NBL1-15123] - Western Blot experiments. Left-Control; Right -Over-expression Lysate for RAD9A
Rad9 antibody detects RAD9A protein at nucleus on HBL435 xenograft by immunohistochemical analysis. Sample: Paraffin-embedded HBL435 xenograft. Rad9 antibody (GTX100078) dilution: 1:500.
Immunofluorescence analysis of paraformaldehyde-fixed HeLa, using Rad9 (GTX100078) antibody at 1:100 dilution.
Sample (30 ug of whole cell lysate) A: A431 (GTX27909) B: Hela 10% SDS PAGE GTX100078 diluted at 1:1000
Rad9 antibody detects RAD9A protein by Western blot analysis.A. 30 µg C2C12 whole cell lysate/extract10 % SDS-PAGERad9 antibody (GTX100078) dilution: 1:500
Rad9 antibody detects RAD9A protein by Western blot analysis.A. 30 µg Rat2 whole cell lysate/extract10 % SDS-PAGERad9 antibody (GTX100078) dilution: 1:1000
HeLa cells were subjected to SDS PAGE followed by western blot with 13035-1-AP(RAD9A antibody) at dilution of 1:500
A549 cells were subjected to SDS PAGE followed by western blot with 13035-1-AP(RAD9A antibody) at dilution of 1:800
HeLa cells were subjected to SDS PAGE followed by western blot with 13035-1-AP(RAD9A antibody) at dilution of 1:1000
MCF7 cells were subjected to SDS PAGE followed by western blot with 13035-1-AP(RAD9A antibody) at dilution of 1:500
Human MCF-7; WB Suggested Anti-RAD9A Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:62500. Positive Control: MCF7 cell lysate. RAD9A is supported by BioGPS gene expression data to be expressed in MCF7.; RAD9A antibody - C-terminal region (AVARP03028_P050) in Human MCF-7 cells using Western Blot
Western Blot: TLK1 Antibody [NBP1-77982] Affinity Purified anti-Tlk-1 antibody shows detection of a band ~64 kDa corresponding to isoform 3 of human Tlk-1 (arrowhead). Specific reactivity with this band is blocked when the antibody is pre-incubated with the immunizing peptide (data not shown). Approximately 30 ug of a HeLa nuclear extract was separated by SDS-PAGE and transferred onto nitrocellulose. After blocking the membrane was probed with the primary antibody diluted to 1:250 for 2h at room temperature followed by washes and reaction with a 1:10,000 dilution of IRDye 800 conjugated Gt-a-Rabbit IgG [H&L] MX for 45 min at room temperature. IRDye800 fluorescence image was captured using the Infrared Imaging System. Other detection systems will yield similar results.
Formalin fixed, paraffin embedded human breast carcinoma stained with RAD9A Antibody Cat.-No AP53568PU-N followed by peroxidase conjugation of the secondary antibody and DAB staining.
Confocal immunofluorescent analysis of RAD9A Antibody Cat.-No AP53568PU-N with 293 cell followed by Alexa Fluor 488-conjugated Goat anti-Rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).
Western blot analysis of RAD9A Antibody Cat.-No AP53568PU-N in 293 cell line lysates (35ug/lane). This demonstrates the Rad9 antibody detected the Rad9 protein (arrow).
Immunohistochemistry-Paraffin: Rad9 Antibody (7B11) [NBP1-47946] - Immunohistochemical staining of paraffin-embedded Carcinoma of lung tissue using anti-RAD9Amouse monoclonal antibody. (Dilution 1:50)
Immunohistochemistry-Paraffin: Rad9 Antibody (7B11) [NBP1-47946] - Immunohistochemical staining of paraffin-embedded Adenocarcinoma of colon tissue using anti-RAD9Amouse monoclonal antibody. (Dilution 1:50)
Immunohistochemistry-Paraffin: Rad9 Antibody (7B11) [NBP1-47946] - Immunohistochemical staining of paraffin-embedded colon tissue using anti-RAD9Amouse monoclonal antibody. (Dilution 1:50)
Immunohistochemistry-Paraffin: Rad9 Antibody (7B11) [NBP1-47946] - Immunohistochemical staining of paraffin-embedded Adenocarcinoma of breast tissue using anti-RAD9A mouse monoclonal antibody. (Dilution 1:50)
Western Blot: Rad9 Antibody (7B11) [NBP1-47946] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RAD9A (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-RAD9A.
Western Blot: Rad9 Antibody (7B11) [NBP1-47946] - Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-anti-RAD9Amonoclonal antibody.
Western Blot: Rad9 [p Ser1260] Antibody [NBP1-77981] Affinity purified phospho-specific antibody to yeast Rad9 at pS1260 was used at a 1:200 dilution incubated overnight at 4° C to detect Rad9 by Western blot. Lanes were loaded with 50 ng each of recombinant GST fusion protein containing S. cerevisiae Rad9
Immunohistochemical staining of paraffin-embedded Carcinoma of lung tissue using anti-RAD9Amouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500434, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of colon tissue using anti-RAD9Amouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500434, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Adenocarcinoma of breast tissue using anti-RAD9A mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500434, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded colon tissue within the normal limits using anti-RAD9Amouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500434, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Carcinoma of pancreas tissue using anti-RAD9Amouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500434, Dilution 1:50)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RAD9A (RC204439, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-RAD9A.
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-anti-RAD9Amonoclonal antibody.
Immunohistochemical staining of paraffin-embedded pancreas tissue within the normal limits using anti-RAD9Amouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500435, Dilution 1:50)
Immunohistochemical staining of paraffin-embedded Ovary tissue within the normal limits using anti-RAD9Amouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 100C for 10min, TA500435, Dilution 1:50)
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY RAD9A (RC204439, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-RAD9A.
Western blot analysis of extracts (35ug) from 9 different cell lines by using anti-anti-RAD9Amonoclonal antibody.
- Quick-Filters:
- Highly Validated (3)
Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA308749 | RAD9A antibody |
||||||
| Rabbit polyclonal antibody to Rad9 (RAD9 homolog A (S. pombe)) | |||||||
 |
Rabbit | IgG | Aff - Purified | Hu, Ms, Rt | ICC/IF, P, WB |
0.1 ml /
€415.00
|
|
| OriGene Technologies, Inc. | |||||||
 +4 additional images |
Highly validated antibody! |
||||||
| TA500434 | RAD9A antibody |
||||||
| anti-RAD9A (RAD9) mouse monoclonal antibody, clone OTI7B11 (formerly 7B11) | |||||||
 |
Mouse | IgG2a | OTI7B11 | Purified | Hu | P, WB |
0.1 ml /
€360.00
|
| OriGene Technologies, Inc. | |||||||
| +6 additional images |
Highly validated antibody!
|
||||||
| TA500435 | RAD9A antibody |
||||||
| anti-RAD9A (RAD9) mouse monoclonal antibody, clone OTI5D9 (formerly 5D9) | |||||||
 |
Mouse | IgG2a | OTI5D9 | Purified | Can, Hu, Mky | P, WB |
0.1 ml /
€379.00
|
| OriGene Technologies, Inc. | |||||||
| +3 additional images |
Highly validated antibody!
|
||||||
| TA301769 | RAD9A antibody |
||||||
| Rabbit Polyclonal Antibody against RAD9 | |||||||
 |
Rabbit | IgG | Purified | Hu | C, WB |
50 µl /
€395.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA302093 | RAD9A (BH3 Domain) antibody |
||||||
| Rabbit Polyclonal Antibody against RAD9A | |||||||
 |
Rabbit | Ig | Purified | Hu, Ms | P, WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies, Inc. | |||||||
| +2 additional images |
|||||||
| TA302588 | RAD9A (C-term) antibody |
||||||
| Goat Polyclonal Antibody against RAD9A | |||||||
 |
Goat | Aff - Purified | Can, Hu, Ms | E, WB |
0.1 mg /
€360.00
|
||
| OriGene Technologies, Inc. | |||||||
| TA324191 | RAD9A antibody |
||||||
| Anti-RAD9A Rabbit Polyclonal Antibody | |||||||
 |
Rabbit | IgG | Purified | Hu, Ms, Rt | WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA336578 | RAD9A antibody |
||||||
| Mouse Monoclonal Rad9 Antibody (93A535) | |||||||
![Western Blot: Rad9 Antibody (93A535) [TA336578] - Western blot analysis of RAD9 recombinant protein using RAD9 antibody at 2 ug/ml. Human tissue TMA was used for this test.](https://m1.acris-antibodies.com/catalog/product/cache/1/small_image/50x50/9df78eab33525d08d6e5fb8d27136e95/OriGene/NB120-13600-1-W.jpg) |
Mouse | IgG1 | 93A535 | Purified | Hu | C, ICC/IF, IP, P, WB |
0.1 mg /
€395.00
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| TA347038 | RAD9A antibody |
||||||
| Mouse Monoclonal RAD9A Antibody | |||||||
 |
Mouse | IgG2b | 3A3-A7-F8 | Purified | WB |
0.1 ml /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
| +1 additional image |
|||||||
| AP05666PU-N | RAD9A antibody |
||||||
 |
Rabbit | IgG | Purified | Ye | E, WB |
50 µg /
€410.00
|
|
| OriGene Technologies GmbH | |||||||
| AP12684PU-N | RAD9A pSer272 antibody |
||||||
 |
Rabbit | Ig | Aff - Purified | Hu | P, WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| +1 additional image |
|||||||
| AP12685PU-N | RAD9A pSer277 antibody |
||||||
 |
Rabbit | Ig | Aff - Purified | Hu | P, WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| +1 additional image |
|||||||
| AP12686PU-N | RAD9A pSer328 antibody |
||||||
 |
Rabbit | Ig | Aff - Purified | Hu | P, WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| +1 additional image |
|||||||
| AP12691PU-N | RAD9A pSer387 antibody |
||||||
 |
Rabbit | Ig | Aff - Purified | Hu | P, WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| +1 additional image |
|||||||
| AP12692PU-N | RAD9A pTyr28 antibody |
||||||
 |
Rabbit | Ig | Purified | Hu | WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| AP13441PU-N | RAD9A (Center) antibody |
||||||
 |
Rabbit | Ig | Purified | Hu | WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| AP53568PU-N | RAD9A antibody |
||||||
 |
Rabbit | Ig | Aff - Purified | Hu | ICC/IF, P, WB |
0.4 ml /
€415.00
|
|
| OriGene Technologies GmbH | |||||||
| +2 additional images |
|||||||
| R1480P | RAD9A (pan reactive) antibody |
||||||
|
Rabbit | Aff - Purified | Ye | E, WB |
0.1 mg /
€515.00
|
||
| OriGene Technologies GmbH | |||||||
| R1481P | RAD9A pSer1260 antibody |
||||||
 |
Rabbit | Aff - Purified | Ye | E, WB |
0.1 mg /
€515.00
|
||
| OriGene Technologies GmbH | |||||||
| +1 additional image |
|||||||
| R1482P | RAD9A pSer1129 antibody |
||||||
 |
Rabbit | Aff - Purified | Ye | E, WB |
0.1 mg /
€515.00
|
||
| OriGene Technologies GmbH | |||||||
